Premium
Photochemistry and Phototoxicity of Fluocinolone 16,17‐Acetonide ¶
Author(s) -
Miolo Giorgia,
Caffieri Sergio,
Daizoppo Daniele,
Ricci Andrea,
Fasani Elisa,
Albini Angelo
Publication year - 2005
Publication title -
photochemistry and photobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.818
H-Index - 131
eISSN - 1751-1097
pISSN - 0031-8655
DOI - 10.1111/j.1751-1097.2005.tb00186.x
Subject(s) - phototoxicity , chemistry , fluocinolone acetonide , photochemistry , radical , drug , reactive oxygen species , irradiation , oxygen , in vitro , nuclear chemistry , pharmacology , biochemistry , organic chemistry , dermatology , medicine , physics , nuclear physics
Fluocinolone 16,17‐acetonide is a corticosteroid used topically to treat various inflammatory skin diseases. Its photoreactivity was studied under UV‐A and UV‐B light in aqueous buffer in the presence of oxygen. This drug is photolabile under UV‐B light and, to a lesser extent, under UV‐A light, which is absorbed far less. In phosphate buffer, approximately 80% of fluocinolone acetonide decomposes after 5 J/cm 2 of UV‐B irradiation, whereas under 30 J/cm 2 of UV‐A light approximately only 20% decomposes. Both the drug and its photoproducts have been evaluated through a battery of in vitro studies and found to cause photohemolysis and induce photodamage to proteins (erythrocyte ghosts, bovine serum albumin) and linoleic acid. In addition, one of the photoproducts (the 17‐hydroperoxy derivative) is highly toxic in the dark. Therefore, both loss of therapeutic activity and light‐induced adverse effects may be expected when patients expose themselves to sunlight after drug administration. A major mechanism for phototoxicity involves radicals forming from drug breakdown, at least under UV‐B, although reactive oxygen species may play a role, particularly under UV‐A.